Corganics® Company Profile

Background

Corganics®, established in January 2020 by pharmaceutical industry executives, is dedicated to bridging the gap between healthcare professionals and their patients in understanding and treating the Endocannabinoid System (ECS). The company specializes in scientifically formulated, physician-advised, broad-spectrum CBD products that meet the highest clinical standards. Corganics' mission is to provide safe, effective, all-natural, organic therapeutic products, exclusively available through healthcare professionals, thereby ensuring quality and trust in cannabinoid therapy.

Key Strategic Focus

Corganics focuses on delivering clinical-grade cannabinoid therapies that are rigorously tested and transparent. The company's core objectives include:

• Product Quality: Ensuring all products are free from binders, fillers, excipients, dyes, or unknown substances.

• Advanced Technology: Utilizing Advanced Lipid Technology (A.L.T.) to enhance CBD absorption.

• Healthcare Integration: Partnering exclusively with healthcare professionals across various specialties, including oncology, orthopedic surgery, dermatology, and primary care, to provide trusted cannabinoid therapies.

Financials and Funding

In November 2021, Corganics secured Series A funding from Altacrest Capital. This investment supports the expansion of its clinical product portfolio and rebranding strategy. The capital is intended to:

• Amplify education on cannabinoid therapy.

• Expand operations and commercial footprint.

• Invest in research and development innovations.

Pipeline Development

Corganics offers a range of clinical CBD products, including:

• Clinical CBD Softgels: Each softgel contains 30mg of broad-spectrum CBD, utilizing A.L.T. for enhanced absorption.

• Clinical CBD Drops: Unflavored drops formulated with broad-spectrum, THC-free hemp extract.

• Clinical CBD Cream: A topical cream combining broad-spectrum hemp extract with vitamin E and aloe vera.

These products are designed to support overall wellness and are available exclusively through healthcare professionals.

Technological Platform and Innovation

Corganics distinguishes itself through:

• Advanced Lipid Technology (A.L.T.): Enhances CBD bioavailability, allowing for up to three times the absorption compared to standard formulations.

• Rigorous Testing: Every batch undergoes third-party laboratory testing for pesticides, heavy metals, potency, and microbials to ensure the highest quality.

• Supercritical CO₂ Extraction: Utilized in a cGMP and NSF-compliant facility to maintain product purity and consistency.

Leadership Team

• Chad Collins: Co-founder and CEO, instrumental in steering the company's mission and strategic direction.

• Reggie Gatewood: Co-founder and President, focusing on bridging the gap between healthcare providers and patients regarding cannabinoid therapy.

• Jared Rose: Appointed Chief Revenue Officer in September 2024, bringing over 25 years of experience in the pharmaceutical and healthcare industries.

Leadership Changes

In September 2024, Jared Rose joined Corganics as Chief Revenue Officer, enhancing the company's leadership with his extensive industry experience.

Competitor Profile

Market Insights and Dynamics

The CBD market reached USD 7.6 billion in 2023 and is projected to surpass USD 36 billion by 2033. This growth is driven by increasing consumer interest in natural and alternative therapies, particularly for pain management, sleep disorders, and anxiety.

Competitor Analysis

Key competitors in the clinical CBD space include:

• Charlotte's Web: Offers a range of CBD products with a focus on quality and transparency.

• Medterra: Provides THC-free CBD products, emphasizing scientific research and quality control.

• CBDistillery: Known for a broad product line and commitment to education and transparency.

These companies focus on product quality, transparency, and consumer education, similar to Corganics' strategic approach.

Strategic Collaborations and Partnerships

Corganics has established significant partnerships to enhance its market position:

• Sure Med Compliance: In August 2024, partnered to improve education and access to clinical CBD products in pain management settings.

• OrthoLoneStar: In March 2023, collaborated to provide patients access to Corganics' clinical CBD therapies across OrthoLoneStar's locations.

• MedResults Network (MRN): In August 2022, partnered to offer products to over 3,400 aesthetic medical practices and med spas.

Operational Insights

Corganics differentiates itself through:

• Exclusive Healthcare Professional Distribution: Ensures product quality and trust by offering products solely through healthcare providers.

• Advanced Technology: A.L.T. enhances product efficacy and absorption.

• Rigorous Testing and Transparency: Commitment to third-party testing and transparency builds trust among healthcare professionals and patients.

Strategic Opportunities and Future Directions

Corganics aims to:

• Expand Product Portfolio: Develop new cannabinoid-based therapies to address a broader range of conditions.

• Enhance Educational Initiatives: Provide comprehensive education to healthcare professionals and patients about the ECS and cannabinoid therapy.

• Strengthen Partnerships: Forge new collaborations to extend market reach and integrate products into various healthcare settings.